Pharmaceutical Manufacturers Grapple With ICH Q3D Implementation
Executive Summary
Pharmaceutical manufacturers say that complying with ICH Q3D presents a host of challenges, and that the more difficult task is conducting a risk assessment rather than actual testing for elemental impurities. Companies are finding that they should allow plenty of time for risk assessments.
You may also be interested in...
It’s Time To ‘Get Moving’ To Meet ICH Q3D Deadline, Industry Told
A pharmaceutical industry official said while it is not too late, manufacturers that have not yet started risk assessments to comply with ICH Q3D for legacy products need to get busy. Official also advised that good risk assessments should make it easier to comply and reduce the need to retest products if new metals are introduced into the manufacturing process.
ICH Q3D Metal Impurities Guidance Issued By FDA, EMA, Health Canada
Regulatory members of the International Council on Harmonization have issued Q3D guidance on metal impurities that, while harmonized, differs in emphasis.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”